The Swiss pharma giant will pay $1.1 billion (CHF883 million) to acquire Myricx Bio, which is developing antibody-drug conjugates for various types of solid tumours.
Myricx Bio was founded in 2019 as a spin-off from Imperial College London and the Francis Crick Institute.
Keystone-SDA
Swiss pharmaceutical giant Novartis has agreed to pay an initial sum of $1.1 billion (CHF883 million) to acquire the British start-up Myricx Bio, which is developing antibody-drug conjugates for various types of solid tumours.
Generated with artificial intelligence.
This content was published on
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)
Patent cliff fuels Novartis' $1.5bn swoop for London biotech
Novartis rileva Myricx Bio in un’operazione fino a 1,5 miliardi di dollari
Novartis: rileva gruppo biotecnologie Myricx Bio per 1,1 mld $
London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
Correction to Novartis Article
Novartis to acquire ADC developer in a deal worth up to $1.5B
Aussie super funds hit the jackpot in $2b UK biotech deal
Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for…
Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.
Novartis has acquired UK biotech Myricx for up to $1.5bn as global drugmakers invest inpromising biotech firms ahead expected…
Da inizio anno sono state concluse 23 operazioni di M&A nel biotech per un controvalore di 94 miliardi di dollari, contro 103…
(Il Sole 24 Ore Radiocor) - Il colosso farmaceutico svizzero Novartis ha rilevato il gruppo britannico delle biotecnologie Myricx…
Novartis has agreed to acquire London biotech Myricx Bio for up to $1.5 billion, believing on its NMT inhibitor payload as a…
